QbD Group
    点播网络研讨会

    IVDR Extension Explained

    Tips & Strategies

    The journey towards adopting the IVD regulations introduced in 2017 has been ongoing for some time, presenting challenges for many in the industry. This session will provide you with the latest updates on the IVDR extension and its impact on your daily operations and long-term strategies. Don’t miss this opportunity to gain valuable insights directly from an expert at the forefront of the field.

    随时观看
    60 分钟
    Regulatory Affairs · In Vitro Diagnostics
    Chinese

    The journey towards adopting the IVD regulations introduced in 2017 has been ongoing for some time, presenting challenges for many in the industry. Acknowledging the potential disruption that can be caused by devices no longer being available, the European Commission introduced initiatives last year to ensure continuity in devices on the market and minimize the impact on patients. Now, as we enter 2024, they are reinforcing these efforts with new measures to facilitate a seamless transition for specific IVDs.

    This session will provide you with the latest updates on the IVDR extension and its impact on your daily operations and long-term strategies. Don’t miss this opportunity to gain valuable insights directly from an expert at the forefront of the field.

    Watch the webinar on demand

    What you'll learn

    • Understanding the proposal
    • Understanding the implications of the IVDR extension and the conditions to be met to make use of the new extended transitional provisions
    • The impact of the gradual roll-out of EUDAMED
    • Information obligation in case of interruption of supply
    • Strategic planning for compliance: Learn strategies to navigate the IVDR transition effectively, including tips for adjusting your day-to-day operations and long-term planning
    • Expert Q&A to address your specific questions

    向最优秀的人学习

    演讲者

    Join us as our expert speakers share valuable insights and practical knowledge drawn from extensive industry experience.

    Kirsten Van Garsse

    Kirsten Van Garsse

    Director Authorised Representative Services & Manager IVD - Regulatory Affairs

    Kirsten Van Garsse obtained her Master’s degree in Biomedical Sciences in 2002 from the Vrije Universiteit Brussel (VUB) and has amassed extensive experience in the In Vitro Diagnostic Medical Device Industry. She joined Qarad, now part of the QbD Group, a consulting company specialized in Regulatory Affairs and Quality Systems for the IVD and Medical Device industry, at the end of 2017. In her role as Director of Authorized Representative Services & Manager of IVD Regulatory Affairs, Kirsten applies her wealth of experience to Regulatory Affairs projects, adeptly translating regulations into compliant business processes and applications. Additionally, she oversees the various Representation Services offered by Qarad, ensuring clients receive expert support in navigating regulatory requirements.

    AP

    Anne Paulussen

    Senior Consultant IVD - Regulatory Affairs

    Anne Paulussen brings nearly 15 years of experience in the pharmaceutical sector. Anne’s extensive experience in both the pharmaceutical and in vitro diagnostics (IVDs) sectors has given her a profound understanding of the interplay between pharmaceuticals and diagnostics. With expertise spanning both fields, Anne offers valuable insights that enhance her contributions to the industry, especially in the field of companion diagnostics. Prior to joining Qarad in 2022 as a Senior Regulatory Consultant for IVDs, Anne served as a Global Regulatory Device Leader at Sanofi, working on drug-device combinations. In her current role, Anne leverages her expertise to advise CROs and pharmaceutical companies on IVDR compliance, regulatory intelligence, and comprehensive training for IVD manufacturers across all facets of IVDR implementation.

    Register here

    Keep watching

    More webinars

    From Strategy to First-in-Human: A Practical Roadmap for Biotech Development 点播网络研讨会

    From Strategy to First-in-Human: A Practical Roadmap for Biotech Development

    Regulatory Affairs2026年3月18日

    Early-stage biotech teams often struggle to translate scientific innovation into first-in-human readiness. This webinar provides practical guidance to help teams build a clear, scalable development pathway that aligns regulatory strategy, CMC, quality, and clinical planning. Reducing risk, avoiding delays, and staying inspection-ready without overbuilding internal structures.

    立即观看

    我们使用 Cookie 来改善您的体验

    我们使用必要的 Cookie 来保证网站功能,以及可选的分析 Cookie 来改善我们的服务。 阅读我们的 隐私政策Cookie 政策.